• MyriadPro Login
  • Register
  • English
  • Français
  • Deutsch
  • Italiano
Myriad Logo
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice CDx Plus
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice CDx Plus (Europe)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
    • News
      • Newsletter signup
      • News center
      • Press releases
      • Events (new?)
      • Media (hold)
        • Articles (hold)
        • Webinars (hold)
        • Podcasts (hold)
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice CDx Plus
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice CDx Plus (Europe)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
    • News
      • Newsletter signup
      • News center
      • Press releases
      • Events (new?)
      • Media (hold)
        • Articles (hold)
        • Webinars (hold)
        • Podcasts (hold)
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form

News Center

News Center
  • Category
    • All
    • Patients
    • Pipeline
    • Products
    • Providers

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

October 16, 2020

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 at...

Continue Reading

American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer

August 21, 2020

SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announc...

Continue Reading

Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction

July 7, 2020

Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and Without Pathogenic Mut...

Continue Reading

New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

June 25, 2020

SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced toda...

Continue Reading

Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer

June 4, 2020

EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy SALT LAKE CITY, June 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:...

Continue Reading

Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients

May 29, 2020

SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announ...

Continue Reading

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

May 20, 2020

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced...

Continue Reading

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer

May 11, 2020

SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced...

Continue Reading

Virtual Testing Options for Patients

April 8, 2020

Myriad Oncology understands that even during these challenging times individuals still need genetic testing to provide critical information for treatment and he...

Continue Reading

Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC

April 6, 2020

More Than 25,000 People in Japan Are Eligible for Genetic Testing SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a lea...

Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Myriad Logo

Health. Illuminated.

  • Contact Us
  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.